As our research “bench” continues to grow, we’re thrilled to welcome two new Research Consortium and two new Scientific Advisory Board members to our team. Each member brings unique expertise to accelerate our progress toward a cure.

Bruce Lamb, Ph.D., of the Cleveland Clinic’s Department of Neurosciences, is the newest addition to our Research Consortium. Dr. Lamb has studied Alzheimer’s disease phenotypes with a focus on developing and characterizing genomic-based mouse models of the disease through the introduction of human AD genes into the germline of mice.

Li-Huei Tsai, Ph.D., director of The Picower Institute for Learning and Memory and Picower professor of neuroscience based at MIT, also joins our Research Consortium. Her research focuses on neuropsychiatric disorders, autism and Alzheimer’s disease.

Vince Groppi, Ph.D., the director of the University of Michigan’s Center for the Discovery of New Medicines in Ann Arbor, joins our Scientific Advisory Board as a leader in pharmaceuticals and biotechnology. He has 30 years of technical and leadership experience in translational pharmacology and drug development.

Ron Petersen, M.D., Ph.D., joins our Scientific Advisory Board. He is director of the Mayo Clinic Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging in Rochester, Minnesota. Dr. Petersen investigates cognition in normal aging, mild cognitive impairment and dementia.

We anticipate great contributions by these remarkable scientists and look forward to sharing them in future publications. The fact that our organization continues to attract such high-caliber researchers is a testament to the breakthroughs we’re making in understanding what causes Alzheimer’s disease and how ultimately to stop it.